Biocept CNSide

Biocept has announced the full commercial launch of CNSide, its cerebrospinal fluid liquid biopsy assay designed to detect and help manage the treatment of cancers that have metastasized to the central nervous system. Initially introduced in January 2020, the test uses Biocept's quantitative tumor cell capture technology, paired with assays to identify actionable molecular treatment targets.

In presentations at recent scientific meetings, Biocept has shared data showing that CNSide could detect tumor cells in about 80 percent of suspect cases, while current cytology methods only capture about 50 percent. The test is currently validated to identify CNS metastases in patients with cancers originating in the lung or breast, but Biocept plans to expand to additional tumor types in the future.